An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Trial Profile

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2018

At a glance

  • Drugs Evinacumab (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions; Registrational
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 02 May 2018 Planned End Date changed from 6 Oct 2022 to 1 Apr 2022.
    • 02 May 2018 Planned primary completion date changed from 6 Oct 2022 to 1 Apr 2022.
    • 17 Jan 2018 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top